Northwest Biotherapeutics, Inc.

Equities

NWBO

US66737P6007

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 14:14:30 2024-05-30 EDT			5-day change	1st Jan Change
0.4562 ^USD	+1.49%		+0.93%	-34.92%

05-10	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-21	Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of Directors	CI

Northwest Biotherapeutics, Inc. Appoints Jean M. Davis as Chief Financial Officer, Chief Accounting Officer and Interim Chief Information Officer

December 13, 2019 at 04:26 pm

Northwest Biotherapeutics, Inc. announced that it appointed Ms. Jean M. Davis as Chief Financial Officer, Chief Accounting Officer and Interim Chief Information Officer of the Company, effective December 9, 2019. Prior to joining the Company, Ms. Davis served as a Risk Advisory Senior Manager of BDO USA LLP.

Latest news about Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of Directors	03-21	CI
Northwest Biotherapeutics, Inc. Announces Retirement of Jerry Jasinowski from the Board of Directors	03-14	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05	CI
Northwest Biotherapeutics Announces Marketing Authorization Application Has Been Submitted to the UK MHRA for DCVax-L for Glioblastoma	12-21	CI
Northwest Biotherapeutics, Inc. announced that it has received $11.005 million in funding from Streeterville Capital, LLC	11-09	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Northwest Biotherapeutics Appoints Linda Liau to its Scientific Advisory Board	23-09-12	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	23-02-27	CI
Transcript : Northwest Biotherapeutics, Inc. - Shareholder/Analyst Call	22-12-30
Northwest Biotherapeutics Sues Citadel Securities, Other Market Market Makers for Alleged Stock Price Manipulation	22-12-01	MT
Northwest Biotherapeutics Reports Positive Top-Line Results from Phase 3 Trial of DCVax®-L for Glioblastoma	22-11-17	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Northwest Biotherapeutics Files $250 Million Mixed Shelf	22-10-19	MT
Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan by MHRA	22-08-23	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09	CI
Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing At Sawston, Uk Facility	22-07-06	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-10	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-01	CI
Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	22-02-28	CI
Northwest Biotherapeutics Announces Commencement of Cancer Vaccine Production At Its Sawston, UK Facility	22-02-17	CI
Northwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing at Sawston, UK Facility	21-12-21	CI

Chart Northwest Biotherapeutics, Inc.

Duration

Period

More charts

Company Profile

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Companyâs wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NORTHWEST BIOTHERAPEUTICS, INC.	-34.92%	545M
VERTEX PHARMACEUTICALS INCORPORATED	+7.97%	114B
REGENERON PHARMACEUTICALS, INC.	+9.63%	104B
ARGENX SE	-1.83%	22.57B
BIONTECH SE	-9.68%	22.5B
GENMAB A/S	-10.39%	17.95B
WUXI APPTEC CO., LTD.	-41.90%	16.48B
BEIGENE, LTD.	-13.86%	15.82B
NEUROCRINE BIOSCIENCES, INC.	+3.23%	13.55B
SAREPTA THERAPEUTICS, INC.	+28.79%	10.99B

Bio Therapeutic Drugs